Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 12/11/2024 | Buy | TD Cowen | ||
| 2/9/2024 | Hold → Buy | Canaccord Genuity | ||
| 4/4/2023 | Underperform → Mkt Perform | Bernstein | ||
| 11/2/2022 | $1.50 | Underperform | Bernstein | |
| 10/26/2022 | Sell → Hold | Canaccord Genuity | ||
| 9/21/2022 | Sell → Hold | Canaccord Genuity | ||
| 6/24/2022 | Neutral → Overweight | Cantor Fitzgerald | ||
| 6/8/2022 | Market Perform → Underperform | BMO Capital Markets |
VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics" or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Interim Chief Financial Officer. Janis Risbin, current CFO, will be stepping away from her full-time role effective today. She will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Mr. Ibbott. "Glen's leadership at Aurora C
A cannabis and beverage alcohol industry executive with more than 25 years of experience, Mr. Jorgensen will lead the unified Canopy USA organization forward with a focus on driving profitable growth across the U.S. With the completed acquisitions of Acreage, Wana, and Jetty, Canopy USA now enters a new chapter of growth across key segments including flower, edibles, vapes, extracts, and through an established retail presence in high potential markets across the Midwest and Northeast BOULDER, Colo., January 6, 2025 /PRNewswire/ - Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the fastest growing states and highest potential segments of the U.S. c
SMITHS FALLS, ON, Sept. 25, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) is pleased to announce today the voting results from its annual general meeting of shareholders held on September 24, 2024 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 1, 2024 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of the direc
NASDAQ | TSX: ACB Achieves Record Annual Global Medical Cannabis Net Revenue1 of $244.4 million, representing 39% YoY growthDelivers Record Adjusted EBITDA1 of $49.7 million, representing 261% YoY growthGenerates Annual Positive Free Cash Flow1 of $9.9 million Sustains Strong Balance Sheet with ~$185.3 million of Cash and Debt-Free Cannabis Business2EDMONTON, AB, June 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2025 periods ending March 31, 2025.
NASDAQ | TSX: ACB EDMONTON, AB, June 3, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2025 on Wednesday, June 18, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, June 18, 2025
Canada cannabis revenue increased 4% in Q4 FY2025 year-over-year, led by 13% growth in Canada medical cannabis Reduced total debt by $293 million or 49% during FY2025 Refined strategy, focus and organizational structure expected to accelerate growth in global medical cannabis and improve commercial execution in Canada adult-use cannabis Additional cost reduction initiatives identified and initiated in Q4 FY2025 are expected to deliver at least $20 million in annualized savings over the next 12-18 months Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the fourth quarter ended March 31, 2025 ("Q4 FY2025") a
4 - Canopy Growth Corp (0001737927) (Issuer)
4 - Canopy Growth Corp (0001737927) (Issuer)
4 - Canopy Growth Corp (0001737927) (Issuer)
6-K - AURORA CANNABIS INC (0001683541) (Filer)
6-K - AURORA CANNABIS INC (0001683541) (Filer)
6-K - AURORA CANNABIS INC (0001683541) (Filer)
TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy
Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy
Bernstein upgraded Canopy Growth from Underperform to Mkt Perform
NASDAQ | TSX: ACB EDMONTON, AB, June 19, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, has become aware of a second instance of misinformation posted on news website, Investing.com. On June 18, 2025, Aurora advised the market that an article posted on Investing.com incorrectly stated that Aurora had agreed to acquire New Zealand-based MedLeaf Therapeutics. Later in the day on June 18, 2025, a second article was posted on Investing.com that incorrectly states that Aurora has
NASDAQ | TSX: ACB EDMONTON, AB, June 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, has become aware of misinformation posted on a news website, incorrectly stating that Aurora has agreed to acquire New Zealand based MedLeaf Therapeutics. The Company has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics with respect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction.
NASDAQ | TSX: ACB Achieves Record Annual Global Medical Cannabis Net Revenue1 of $244.4 million, representing 39% YoY growthDelivers Record Adjusted EBITDA1 of $49.7 million, representing 261% YoY growthGenerates Annual Positive Free Cash Flow1 of $9.9 million Sustains Strong Balance Sheet with ~$185.3 million of Cash and Debt-Free Cannabis Business2EDMONTON, AB, June 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2025 periods ending March 31, 2025.
SC 13D/A - Canopy Growth Corp (0001737927) (Subject)
SC 13D/A - Canopy Growth Corp (0001737927) (Subject)
SC 13D/A - Canopy Growth Corp (0001737927) (Subject)